-

Shareholder Alert: Robbins LLP Announces It Is Investigating Allakos, Inc. (ALLK) for Misleading Shareholders

SAN DIEGO & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating Allakos, Inc. (NYSE: ALLK) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. Allakos is a clinical stage biopharmaceutical company that focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases.

If you suffered a loss as a result of Allakos' misconduct, click here.

Allakos, Inc. (ALLK) Accused of Releasing Compromised Trial Results

On August 5, 2019, Allakos announced that its drug AK002 had met all pre-specified primary and secondary endpoints in its Phase 2 clinical trial (the "ENIGMA Trial"). Then, on December 18, 2019, Seligman Investments published a report identifying several concerns with the ENIGMA trial, including but not limited to "flagrant nepotism in key clinical roles," "poor controls as well as Allakos' role in running the study itself," and trial results that were compromised by ample use of steroids, glaring omissions, cherry-picked measures, and statistical gimmicks and obfuscation. Since this news, shares of Allakos have precipitously declined and currently trade at around $55.00, representing a 60% decline from its class period high of $137.73.

Allakos, Inc. (ALLK) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

 

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:ALLK

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Calix, Inc. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Calix, Inc. (NYSE: CALX) securities between January 28, 2026 and April 21, 2026. Calix engages in the provision of cloud and software platforms, and systems and services.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations that Calix,...

Investor Notice: Robbins LLP Informs Investors of the Zoetis Inc. Class Action  

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Zoetis Inc. (NYSE: ZTS) securities between January 14, 2025 and May 6, 2026. Zoetis is an animal health company that develops, manufactures, and sells vaccines, medicines, diagnostics, biopharmaceuticals, and digital solutions for companion animals and livestock.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a...

Investor Notice: Robbins LLP Informs Investors of the AeroVironment, Inc. Class Action  

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired AeroVironment, Inc. (NASDAQ: AVAV) securities between June 25, 2025 and March 10, 2026. AeroVironment operates as a defense technology provider delivering integrated capabilities across air, land, sea, space, and cyber.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robb...
Back to Newsroom